Chronic Obstructive Pulmonary Disease – Landscape & Forecast – Disease Landscape & Forecast

The chronic obstructive pulmonary disease (COPD) therapy market is continuing its gradual shift away from long-acting beta2 agonist/inhaled corticosteroid fixed-dose combinations (LABA/ICSFDCs) toward LABA/long-acting muscarinic antagonist (LAMA) FDCs and even LABA/LAMA/ICSFDCs, but current and emerging generics will have a significant impact on this trend. Some branded generic and generic LABA/ICSFDCs have already launched in the United States and Europe, and more will reach the market in the near future; because cost remains a significant driver, we expect competition from these generics to affect the uptake of both LABA/LAMA and LABA/LAMA/ICSFDCs. Physicians are eager to have alternative treatments for this chronic disease, and the development of novel drug classes continues.

QUESTIONS ANSWERED

  • How will markets react to the launch / uptake of generic LABA/ICSFDCs and tiotropium? Will there be significant country-to-country differences in the uptake of these generics?
  • Will LABA/LAMAFDCs continue to gain market share, or will generic therapies or branded LABA/LAMA/ICSFDCs threaten these agents?
  • What proportion of patients currently receive a combination of two or more therapies in separate inhalers? How many receive triple therapy, and will these patients be shifted to FDCs?
  • Which emerging therapies have the most potential for uptake? Will nebulized therapies be accepted?

PRODUCT DESCRIPTION

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Chronic Obstructive Pulmonary Disease - Landscape & Forecast - Disease Landscape & Forecast
    • Key Updates
      • Q4 2021
        • November 2021
      • Q3 2021
        • September 2021
        • August 2021
        • July 2021
      • Q2 2021
        • June 2021
        • May 2021
        • April 2021
      • Q1 2021
        • March 2021
        • February 2021
        • January 2021
      • Q4 2020
        • December 2020
    • Key Findings
      • Market Outlook
        • Key Findings
          • Market Share of COPD Drug Classes: 2020
          • Market Share of COPD Drug Classes: 2030
          • COPD SWOT Analysis
        • Market Drivers and Constraints
          • What Factors Are Driving the Market for Chronic Obstructive Pulmonary Disease?
          • What Factors Are Constraining the Market for Chronic Obstructive Pulmonary Disease?
          • Patient Share of Select Drug Classes for Mild to Moderate COPD in the G7: 2020-2030
          • Patient Share of Select Drug Classes for Severe to Very Severe COPD in the G7: 2020-2030
        • Drug-Class-Specific Trends
          • Brand and Generic Patient Share of Tiotropium in COPD: 2020-2030
          • Major-Market Sales of LAMAs in COPD: 2020-2030
          • Brand and Generic Sales of LABA/ICSs in COPD: 2020-2030
          • U.S. Patient Share of LABA/ICS Combinations in COPD: 2020-2030
          • EU5 Patient Share of LABA/ICS Combinations in COPD: 2020-2030
          • Japan Patient Share of LABA/ICS Combinations in COPD: 2020-2030
          • Major-Market Sales and Patient Share of LABA/LAMA Combinations for COPD: 2020-2030
          • Major-Market Patient Share of LABA/LAMA/ICS FDCs for Mild to Moderate COPD: 2020-2030
          • Major-Market Patient Share of LABA/LAMA/ICS FDCs for Severe to Very Severe COPD: 2020-2030
      • Forecast
        • Market Forecast Assumptions - COPD 2020-2030 - November 2021
          • Brand and Generic Patient Share of Tiotropium in COPD: 2020-2030
          • Major-Market Sales of LAMAs in COPD: 2020-2030
          • Brand and Generic Sales of LABA/ICSs in COPD: 2020-2030
          • U.S. Patient Share of LABA/ICS Combinations in COPD: 2020-2030
          • EU5 Patient Share of LABA/ICS Combinations in COPD: 2020-2030
          • Japan Patient Share of LABA/ICS Combinations in COPD: 2020-2030
          • Major-Market Sales and Patient Share of LABA/LAMA Combinations for COPD: 2020-2030
          • Major-Market Patient Share of LABA/LAMA/ICS FDCs for Mild to Moderate COPD: 2020-2030
          • Major-Market Patient Share of LABA/LAMA/ICS FDCs for Severe to Very Severe COPD: 2020-2030
        • Market Forecast Dashboard - COPD 2020-2030 - November 2021
          • Brand and Generic Patient Share of Tiotropium in COPD: 2020-2030
          • Major-Market Sales of LAMAs in COPD: 2020-2030
          • Brand and Generic Sales of LABA/ICSs in COPD: 2020-2030
          • U.S. Patient Share of LABA/ICS Combinations in COPD: 2020-2030
          • EU5 Patient Share of LABA/ICS Combinations in COPD: 2020-2030
          • Japan Patient Share of LABA/ICS Combinations in COPD: 2020-2030
          • Major-Market Sales and Patient Share of LABA/LAMA Combinations for COPD: 2020-2030
          • Major-Market Patient Share of LABA/LAMA/ICS FDCs for Mild to Moderate COPD: 2020-2030
          • Major-Market Patient Share of LABA/LAMA/ICS FDCs for Severe to Very Severe COPD: 2020-2030
      • Etiology and Pathophysiology
        • Disease Overview
          • Etiology
            • Causative Factors for COPD
          • Pathophysiology
            • Mechanisms Contributing to Symptoms and Progression of COPD
            • Lung Anatomy and Pathogenic Processes in COPD
            • Inflammatory Mechanisms of COPD
          • Disease Progression
            • Key Pathways and Drug Targets
              • Potential Biomarkers of COPD
          • Epidemiology
            • Key Findings
              • Epidemiology Populations
                • Disease Definition
                • Methods
                • Sources Used for Total Prevalent Cases of COPD
                • Total Prevalent Cases of COPD : 2020-2030 (Thousands)
                • Disease Definition
                • Methods
                • Sources Used for Diagnosed Prevalent Cases of COPD
                • Diagnosed Prevalent Cases of COPD: 2020-2030 (Thousands)
                • Disease Definition
                • Methods
                • Sources Used for COPD Segmented by Severity
                • Diagnosed Prevalent Cases of Mild to Moderate COPD: 2020-2030 (Thousands)ttttttt
                • Diagnosed Prevalent Cases of Severe to Very Severe COPD: 2020-2030 (Thousands)tttttttttt
                • Number of Drug-Treated Prevalent Cases of Mild to Moderate COPD in the Major Pharmaceutical Markets: 2020-2030 (Thousands)
                • Number of Drug-Treated Prevalent Cases of Severe to Very Severe COPD in the Major Pharmaceutical Markets: 2020-2030 (Thousands)
                • Disease Definition
                • Methods
                • Sources Used for Acute Exacerbations of COPD
                • Acute Exacerbations of COPD: 2020-2030
                • Disease Definition
                • Methods
                • Sources Used for Eosinophilic COPD
                • Diagnosed Prevalent Cases of Eosinophilic COPD: 2020-2030 (Thousands)
            • Current Treatment
              • Key Findings
                • Treatment Goals
                  • Key Endpoints Used in Clinical Trials for COPD
                • Key Current Therapies
                  • Overview
                  • Mechanism of Action of Key Current Drug Classes Used for COPD
                  • Current Treatments Used for COPD
                  • Market Events Impacting the Use of Key Current Therapies in COPD
                  • Advantages and Disadvantages of Tiotropium
                  • Expert Insight: Tiotropium
                  • Advantages and Disadvantages of Aclidinium
                  • Expert Insight: Aclidinium
                  • Advantages and Disadvantages of Glycopyrronium
                  • Expert Insight: Glycopyrronium
                  • Advantages and Disadvantages of Nebulized Glycopyrronium
                  • Expert Insight: Nebulized Glycopyrronium
                  • Advantages and Disadvantages of Revefenacin
                  • Expert Insight: Revefenacin
                  • Advantages and Disadvantages of Umeclidinium
                  • Expert Insight: Umeclidinium
                  • Advantages and Disadvantages of Indacaterol
                  • Expert Insight: Indacaterol
                  • Advantages and Disadvantages of Olodaterol
                  • Expert Insight: Olodaterol
                  • Advantages and Disadvantages of Indacaterol / Glycopyrronium
                  • Expert Insight: Indacaterol / Glycopyrronium
                  • Advantages and Disadvantages of Vilanterol / Umeclidinium
                  • Expert Insight: Vilanterol / Umeclidinium
                  • Advantages and Disadvantages of Formoterol / Aclidinium
                  • Expert Insight: Formoterol / Aclidinium
                  • Advantages and Disadvantages of Olodaterol / Tiotropium
                  • Expert Insight: Olodaterol / Tiotropium
                  • Advantages and Disadvantages of Formoterol / Glycopyrronium
                  • Expert Insight: Formoterol / Glycopyrronium
                  • Advantages and Disadvantages of Salmeterol / Fluticasone Propionate
                  • Expert Insight: Salmeterol / Fluticasone Propionate
                  • Advantages and Disadvantages of Formoterol / Budesonide
                  • Expert Insight: Formoterol / Budesonide
                  • Advantages and Disadvantages of Vilanterol / Fluticasone Furoate
                  • Expert Insight: Vilanterol / Fluticasone Furoate
                  • Advantages and Disadvantages of Formoterol / Glycopyrronium / Beclomethasone
                  • Expert Insight: Formoterol / Glycopyrronium / Beclomethasone
                  • Advantages and Disadvantages of Vilanterol / Umeclidinium / Fluticasone Furoate
                  • Expert Insight: Vilanterol / Umeclidinium / Fluticasone Furoate
                  • Advantages and Disadvantages of Formoterol / Glycopyrronium / Budesonide
                  • Expert Insight: Formoterol / Glycopyrronium / Budesonide
                  • Advantages and Disadvantages of Roflumilast
                  • Expert Insight: Roflumilast
                  • Advantages and Disadvantages of Short-Acting Bronchodilators
                  • Expert Insight: Short-Acting Bronchodilators
                  • Advantages and Disadvantages of Methylxanthines
                  • Expert Insight: Methylxanthines
                • Medical Practice
                  • Overview
                  • Factors Influencing Drug Selection in COPD
                  • Inhaler Devices for COPD
                  • Treatment Decision Tree for COPD: United States
                  • Treatment Decision Tree for COPD: Europe
                  • Treatment Decision Tree for COPD: Japan
              • Unmet Need Overview
                • Current and Future Attainment of Unmet Needs in Chronic Obstructive Pulmonary Disease
                • Top Unmet Needs in Chronic Obstructive Pulmonary Disease: Current Attainment and Future Attainment
                • Expert Insight: Unmet Needs in Chronic Obstructive Pulmonary Disease
              • Emerging Therapies
                • Key Findings
                  • Key Emerging Therapies
                    • Key Therapies in Development for COPD
                    • Estimated Launch Dates of Key Emerging Therapies for the Treatment of COPD
                    • Dupilumab Profile
                    • Analysis of the Clinical Development Program for Dupilumab
                    • Expert Insight: Dupilumab
                    • Expectations for Launch and Sales Opportunity of Dupilumab in COPD
                    • Benralizumab Profile
                    • Analysis of the Clinical Development Program for Benralizumab
                    • Expert Insight: Benralizumab
                    • Expectations for Launch and Sales Opportunity of Benralizumab in COPD
                    • Mepolizumab Profile
                    • Analysis of the Clinical Development Program for Mepolizumab
                    • Expert Insight: Mepolizumab
                    • Expectations for Launch and Sales Opportunity of Mepolizumab in COPD
                    • Ensifentrine Profile
                    • Analysis of the Clinical Development Program for Ensifentrine
                    • Expert Insight: Ensifentrine
                    • Expectations for Launch and Sales Opportunity of Ensifentrine in COPD
                    • Itepekimab Profile
                    • Analysis of the Clinical Development Program for Itepekimab
                    • Expert Insight: Itepekimab
                    • Expectations for Launch and Sales Opportunity of Itepekimab in COPD
                  • Early-Phase Pipeline Analysis
                    • Select Compounds in Early-Phase Development for COPD
                • Access & Reimbursement Overview
                  • Region-Specific Reimbursement Practices
                    • Key Market Access Considerations in COPD: United States
                    • General Reimbursement Environment: United States
                    • Key Market Access Considerations in COPD: EU5
                    • General Reimbursement Environment: EU5
                    • Key Market Access Considerations in COPD: Japan
                    • General Reimbursement Environment: Japan
                • Appendix
                  • COPD Bibliography

              launch Related Market Assessment Reports